Processa Pharmaceuticals, Inc. (PCSA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Processa Pharmaceuticals, Inc. (PCSA) closed at USD 1.62 on 2026-10-14, a change of -79.6 % over the past year, with a market capitalization of USD 4.7M.

Processa Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Processa Pharmaceuticals, Inc. key figures

Previous close

USD 1.62 (2026-10-14)

1-year change

-79.6 %

Market cap

USD 4.7M

Enterprise value

USD 4.5M

P/E ratio (trailing)

-0.41

P/E ratio (forward)

-0.45

EPS (trailing)

-4.09

EPS (forward)

-3.75

PEG ratio

n/a

Price to book

-14.74

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.16

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Processa Pharmaceuticals, Inc. and compare it with other stocks.